Correction: Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Is there added predictive value of hepatic and biliary function data from gadoxetate-enhanced MRI for outcomes in primary sclerosing cholangitis (PSC)?

  • By

  • Kumaresan Sandrasegaran

  • Amar S. Shah

  • Cole P. Thompson

  • Channa R. Jayasekera

  • Elizabeth J. Carey

  • Ayana Jain

  • Aubrey N. Silva

  • Suhaas R. Bonkur

  • Anshuman J. Panda

  • Sudhakar K. Venkatesh

  • Alvin C. Silva

  • September 30, 2026

Share

Clinical Scorecard: Correction: Is there added predictive value of hepatic and biliary function data from gadoxetate-enhanced MRI for outcomes in primary sclerosing cholangitis (PSC)?

At a Glance

CategoryDetail
ConditionPrimary Sclerosing Cholangitis (PSC)
Key MechanismsGadoxetate-enhanced MRI for assessing hepatic and biliary function
Target PopulationPatients with primary sclerosing cholangitis
Care SettingRadiology

Key Highlights

  • Correction of author name from Channa R. Jayasekara to Channa R. Jayasekera
  • Published online on 27 June 2026
  • Original article underwent correction

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified

          Not specified

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Related Content